The biotech company, listed on the Hong Kong bourse in December, has held early talks about a secondary listing on the Abu Dhabi Securities Exchange (ADX) this year.
Bloomberg reported, citing unidentified sources, the story.
Insilico will become the first company without formal operations inside the GCC to list shares on a regional exchange if the listing goes ahead.
A direct listing is initially possible, though Insilico may opt to raise additional capital, the report said.
Several Abu Dhabi-based investors participated in the biotech company’s initial public offering, raising $337M in total last December.
Insilico announced its first preclinical candidate in the UAE earlier in April.
Insilico’s development to foster greater financial ties with Abu Dhabi arrives as ADX deepens cooperation with East Asian financial markets.
In September 2025, the ADX signed an agreement with Hong Kong Exchanges and Clearing Limited to deepen cooperation by exploring dual listings, cross-border financing and mechanisms to facilitate investment.
Stay Up to Date with the Latest Updates at Finance ME
Dubai Introduces Second Stimulus Package Totalling $408M
EDGE’s Rodrigo Torres on Risk, Sovereignty and Defence Finance in a Multipolar World
ADGM Updates 2026 AML and CTF Guidelines for LPAs
